REG - Arecor Therapeutics - Notice of Interim Results

Arecor TherapeuticsAnnouncement

Wed 09:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250924:nRSX6175Aa&default-theme=true

RNS Number : 6175A  Arecor Therapeutics PLC  24 September 2025

Arecor Therapeutics plc

("Arecor" or the "Company")

 

Notice of Interim Results

 

Cambridge, UK, 24 September 2025: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical company focused on drug development and delivery in diabetes
and other cardiometabolic diseases, will announce its interim results for the
six months ended 30 June on Thursday 25 September 2025.

Dr Sarah Howell, Chief Executive Officer, and David Ellam, Chief Financial
Officer, will host a webcast for analysts and institutional investors at 3pm
UK time on Thursday 25 September 2025. To register, please contact
arecor@vigoconsulting.com (mailto:arecor@vigoconsulting.com) . A copy of the
interim results presentation will be released after the meeting on the Company
website at www.arecor.com (http://www.arecor.com) .

 

-ENDS-

For more information, please contact:

 

 Arecor Therapeutics plc                                 +44 (0) 1223 426060

Dr Sarah Howell, Chief Executive Officer

David Ellam, Chief Financial Officer                   info@arecor.com (mailto:info@arecor.com)

 Singer Capital Markets Advisory LLP (NOMAD and Broker)  +44 (0) 20 7496 3000
 Phil Davies, Sam Butcher

 Vigo Consulting                                         +44 (0) 20 7390 0230
 Melanie Toyne-Sewell, Rozi Morris

                                                         arecor@vigoconsulting.com (mailto:arecor@vigoconsulting.com)

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a clinical stage biopharmaceutical company focused
on drug development and delivery in diabetes and other cardiometabolic
diseases. The Company is applying its proprietary technology platform,
Arestat™, to develop a portfolio of proprietary products, as well as working
with leading pharmaceutical and biotechnology companies to deliver therapeutic
products. Its lead product is AT278, the only ultra-concentrated (500U/mL)
ultra-rapid acting insulin which is being co-developed with a US Automated
Insulin Delivery pump device partner. Arecor is also developing a novel oral
delivery platform for peptides (e.g. GLP-1 receptor agonists) targeting the
obesity and diabetes markets. The Company is listed on AIM (AIM: AREC) and is
based in Cambridge, UK.  For further details please see www.arecor.com
(http://www.arecor.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORFIFLTALISFIE